Global Minimal Residual Disease Testing Market size study, by Offering, by Technology, by Application, by Sample Type, by Customer Type and Regional Forecasts 2022-2032

Description

The Global Minimal Residual Disease Testing Market is valued at approximately USD 1.27 billion in 2023 and is expected to grow with a robust compound annual growth rate (CAGR) of 12.2% over the forecast period 2024-2032. Minimal Residual Disease (MRD) testing is a cutting-edge diagnostic technology instrumental in oncology for detecting residual cancer cells after treatment, which assists in tailoring further treatment plans and reducing the risk of relapse. It is gaining traction in clinical and research applications, with increasing adoption in personalized medicine and targeted cancer therapies.

The growing prevalence of cancer globally, coupled with the rising adoption of MRD testing in hematological malignancies, underpins the market's growth. The rapid evolution of molecular diagnostic technologies, alongside supportive regulatory frameworks, has facilitated the integration of MRD testing in cancer treatment pathways. The recurrent use of assays and reagents in these tests ensures the dominance of this segment in the market.

The expanding focus on precision medicine has further augmented the role of MRD testing in validating targeted therapies. The U.S. Food and Drug Administration's approval of personalized treatments for oncology highlights this trend. This progress signifies a paradigm shift in oncology care, aiming to enhance therapeutic efficacy and long-term patient outcomes.

Geographically, the Asia-Pacific region is poised to experience the fastest growth during the forecast period due to a burgeoning healthcare infrastructure, increasing cancer prevalence, and government-led cancer screening initiatives. In contrast, North America continues to hold the largest market share, fueled by technological advancements and substantial investments in cancer research.

Major market players included in this report are:

Illumina, Inc.
Qiagen N.V.
PerkinElmer, Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
Natera, Inc.
Bio-Rad Laboratories, Inc.
Adaptive Biotechnologies Corporation
Sysmex Corporation
Integrated DNA Technologies, Inc.
Twist Bioscience Corporation
Invivoscribe, Inc.
Danaher Corporation
Agilent Technologies, Inc.
Oxford Nanopore Technologies

The detailed segments and sub-segment of the market are explained below:

By Offering:

Assays & Reagents
Instruments
Software & Services

By Technology:

Flow Cytometry
Polymerase Chain Reaction
Next-Generation Sequencing
Other Technologies

By Application:

Blood Cancers
- Lymphoma
- Leukemia
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Other Leukemias
- Multiple Myeloma
- Other Blood Cancers
Solid Tumors

By Sample Type:

Blood
Bone Marrow
Other Sample Types

By Customer Type:

Pharmaceutical & Biopharmaceutical Companies
Hospitals
Diagnostic Laboratories
Academic & Research Institutions

By Region:

North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Competitive landscape with information on major players.
Recommendations on future market approaches and strategic business insights.

Chapter 1. Global Minimal Residual Disease Testing Market Executive Summary

1.1. Global Minimal Residual Disease Testing Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Offering
- 1.3.2. By Technology
- 1.3.3. By Application
- 1.3.4. By Sample Type
- 1.3.5. By Customer Type
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Minimal Residual Disease Testing Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Minimal Residual Disease Testing Market Dynamics

3.1. Market Drivers
- 3.1.1. Growing Incidence of Cancer
- 3.1.2. Rising Adoption of Personalized Oncology Medicine
- 3.1.3. Increasing Investments in MRD Research and Development
3.2. Market Challenges
- 3.2.1. High Costs of Minimal Residual Disease Testing
- 3.2.2. Validation Complexity and Lack of Skilled Professionals
3.3. Market Opportunities
- 3.3.1. Integration of MRD Testing with AI and Big Data Analytics
- 3.3.2. Expansion in Solid Tumor Applications
3.4. Market Trends
- 3.4.1. Adoption of Digital PCR
- 3.4.2. Development of Multiomics Approaches for Cancer Detection

Chapter 4. Global Minimal Residual Disease Testing Market Industry Analysis

4.1. Porter's Five Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Future Perspective of Porter's Five Forces Model
4.2. PESTEL Analysis
- 4.2.1. Political Factors
- 4.2.2. Economic Factors
- 4.2.3. Social Factors
- 4.2.4. Technological Factors
- 4.2.5. Environmental Factors
- 4.2.6. Legal Factors
4.3. Top Investment Opportunities
4.4. Key Winning Strategies
4.5. Disruptive Trends

Chapter 5. Global Minimal Residual Disease Testing Market Size & Forecasts by Offering (2022-2032)

5.1. Segment Dashboard
5.2. Global Minimal Residual Disease Testing Market: Offering Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Assays & Reagents
- 5.2.2. Instruments
- 5.2.3. Software & Services

Chapter 6. Global Minimal Residual Disease Testing Market Size & Forecasts by Technology (2022-2032)

6.1. Segment Dashboard
6.2. Global Minimal Residual Disease Testing Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Flow Cytometry
- 6.2.2. Polymerase Chain Reaction
- 6.2.3. Next-Generation Sequencing
- 6.2.4. Other Technologies

Chapter 7. Global Minimal Residual Disease Testing Market Size & Forecasts by Application (2022-2032)

7.1. Segment Dashboard
7.2. Global Minimal Residual Disease Testing Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Blood Cancers
  - 7.2.1.1. Lymphoma
  - 7.2.1.2. Leukemia
    - 7.2.1.2.1. Acute Lymphoblastic Leukemia (ALL)
    - 7.2.1.2.2. Chronic Lymphocytic Leukemia (CLL)
    - 7.2.1.2.3. Other Leukemias
  - 7.2.1.3. Multiple Myeloma
  - 7.2.1.4. Other Blood Cancers
- 7.2.2. Solid Tumors

Chapter 8. Global Minimal Residual Disease Testing Market Size & Forecasts by Sample Type (2022-2032)

8.1. Segment Dashboard
8.2. Global Minimal Residual Disease Testing Market: Sample Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Blood
- 8.2.2. Bone Marrow
- 8.2.3. Other Sample Types

Chapter 9. Global Minimal Residual Disease Testing Market Size & Forecasts by Customer Type (2022-2032)

9.1. Segment Dashboard
9.2. Global Minimal Residual Disease Testing Market: Customer Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 9.2.1. Pharmaceutical & Biopharmaceutical Companies
- 9.2.2. Hospitals
- 9.2.3. Diagnostic Laboratories
- 9.2.4. Academic & Research Institutions

Chapter 10. Global Minimal Residual Disease Testing Market Size & Forecasts by Region (2022-2032)

10.1. North America Minimal Residual Disease Testing Market
- 10.1.1. U.S. Minimal Residual Disease Testing Market
- 10.1.2. Canada Minimal Residual Disease Testing Market
10.2. Europe Minimal Residual Disease Testing Market
- 10.2.1. U.K. Minimal Residual Disease Testing Market
- 10.2.2. Germany Minimal Residual Disease Testing Market
- 10.2.3. France Minimal Residual Disease Testing Market
- 10.2.4. Spain Minimal Residual Disease Testing Market
- 10.2.5. Italy Minimal Residual Disease Testing Market
- 10.2.6. Rest of Europe Minimal Residual Disease Testing Market
10.3. Asia-Pacific Minimal Residual Disease Testing Market
- 10.3.1. China Minimal Residual Disease Testing Market
- 10.3.2. India Minimal Residual Disease Testing Market
- 10.3.3. Japan Minimal Residual Disease Testing Market
- 10.3.4. Australia Minimal Residual Disease Testing Market
- 10.3.5. South Korea Minimal Residual Disease Testing Market
- 10.3.6. Rest of Asia Pacific Minimal Residual Disease Testing Market
10.4. Latin America Minimal Residual Disease Testing Market
- 10.4.1. Brazil Minimal Residual Disease Testing Market
- 10.4.2. Mexico Minimal Residual Disease Testing Market
- 10.4.3. Rest of Latin America Minimal Residual Disease Testing Market
10.5. Middle East & Africa Minimal Residual Disease Testing Market
- 10.5.1. Saudi Arabia Minimal Residual Disease Testing Market
- 10.5.2. South Africa Minimal Residual Disease Testing Market
- 10.5.3. Rest of Middle East & Africa Minimal Residual Disease Testing Market

Chapter 11. Competitive Intelligence

11.1. Key Company SWOT Analysis
- 11.1.1. Illumina, Inc.
- 11.1.2. Qiagen N.V.
- 11.1.3. Thermo Fisher Scientific, Inc.
11.2. Top Market Strategies
11.3. Company Profiles
- 11.3.1. Adaptive Biotechnologies Corporation
- 11.3.2. F. Hoffmann-La Roche Ltd.
- 11.3.3. Natera Inc.
- 11.3.4. Bio-Rad Laboratories, Inc.
- 11.3.5. Sysmex Corporation
- 11.3.6. Twist Bioscience Corporation

Chapter 12. Research Process

12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
12.2. Research Attributes